Page 36 - Priority Review News Today

Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce...

The FDA has accepted for Priority Review the NDA for cefepime-taniborbactam for the treatment of adults with complicated UTI, including pyelonephritis.

FDA approval of ZILBRYSQ® (zilucoplan) has been granted for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-ac...

UCB announces U.S. FDA approval of ZILBRYSQ[®] for the treatment of adults with generalized myasthenia gravis FDA approval of ZILBRYSQ® has been granted...

AstraZeneca’s supplemental new drug application (sNDA) for lead lung cancer drug Tagrisso (Osimertinib) in combination with chemotherapy has been accepted and granted priority review in the US.

FDA approval of ZILBRYSQ® has been granted for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody-positive1ZILBRYSQ is the first...

Ascentage Pharma announced that it has entered into a clinical collaboration with AstraZeneca Investment Co., Ltd. . The two companies will jointly conduct a registrational Phase III study of the...

AstraZenecas supplemental New Drug Application for Tagrisso in combination with chemotherapy has been accepted and granted Priority Review in the US for the treatment of adult patients with...

Benzinga Bitcoin Spiked On False ETF Approval Rumor Bitcoin (BTC/USD), the ace cryptocurrency, spiked on unverified reports of the approval of an iShares Bitcoin ETF. BlackRock said the information is false, according to Fox Business journalist Eleanor Terrett. The company's Bitcoin ETF application is still under review, BlackRock, which owns iShares, told Fox. Albemarle Backs Out Of Acquisition Offer For Australia's Liontown Resources Mining giant Albemarle Corporation (NYSE: ALB) sai...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2023, taking place on October 20-24, 2023 in Madrid, Spain...